Pain Medicine Experts Recommend Safe and Responsible Use of Acetaminophen

/PRNewswire/ -- In response to the advisory committee's recommendations to the U.S. Food and Drug Administration (FDA) to put new restrictions on acetaminophen this week, physician leaders from the American Academy of Pain Medicine (AAPM), have released the following statement:

The American Academy of Pain Medicine (AAPM), which represents the
medical specialty of Pain Medicine, supports the safe and responsible
use of acetaminophen both in over-the-counter and prescription
medicines. While there are risks associated with the misuse of
acetaminophen, the benefits to patients suffering from both
short-term and chronic pain are significant.

The misuse and abuse of both over-the-counter and prescription
medicines are significant social and medical problems that must be
addressed responsibly. But, the under-treatment of pain is also a
longstanding and significant medical and social problem that also
must be addressed responsibly.

AAPM recognizes that analgesics that combine acetaminophen and an
opioid do pose additional risk for patients with pain conditions
that require doses of the opioid component for sufficient pain relief
that exceed safe doses of the acetaminophen component.

AAPM supports measures that reduce the risk of misuse and abuse of
medications without deterring access to appropriate pain care for
legitimate patients and the need for physicians to adhere to
responsible analgesic prescribing practices. The Academy will
continue to work towards these goals through advocacy, research,
promotion of best clinical practices, and continuing medical
education.

AAPM, founded in 1983, is the recognized authority on the evaluation
and care of patients with pain. It is a professional community of
physicians with a sustained interest in pain disorders and their
management, with a background in related specialties such as
anesthesiology, internal medicine, neurology, neurosurgery,
orthopedic surgery, physiatry, family practice, and psychiatry.

-----
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page

Prescription Drug Benefits for Medicare Patients with Cancer to Cost More in 2009

/PRNewswire-USNewswire/ -- People with cancer enrolled in Medicare Part D plans will spend more out-of-pocket for their Part D drugs and face increased restrictions on access to them in 2009, according to new research released today by Avalere Health and the American Cancer Society Cancer Action Network (ACS CAN).

The Avalere-ACS CAN research found that Medicare stand-alone prescription drug plans (PDPs) have been increasingly shifting name-brand oral cancer drugs to higher formulary tiers over the last four years, meaning that with each year, the products have cost more for consumers.

In 2009, the large majority of PDPs placed name-brand oral oncology products -- including Gleevec, Sutent, Tarceva, Thalomid, and Tykerb -- on specialty tiers that require cost sharing of 26 percent to 35 percent for each prescription. For example, 84 percent of PDP enrollees are in plans that put Gleevec -- a name-brand drug used to treat leukemia and other forms of cancer -- on their most expensive tiers (fourth or higher) in 2009, up from 39 percent in 2006.

"This pattern of shifting the costs of branded medications to patients needs to be scrutinized, especially in light of the economic difficulty being experienced by so many seniors," said Valerie Barton, a vice president at Avalere Health.

"Shifts in drug coverage can limit access to treatment for people with cancer, significantly reducing their treatment options or even requiring a stoppage of treatment," said Daniel E. Smith, president of ACS CAN. "We urge policymakers to pay close attention to how these changes impact people with cancer. At the same time, it is critical that people with cancer understand their health coverage and the potential hurdles that may impact their treatment."

In addition to changing tier placement, PDPs in 2009 are increasing their use of prior authorization to control access to branded cancer drugs. The Avalere-ACS CAN research found that Gleevec had the largest increase in the number of PDPs requiring prior authorization, with 70 percent of plans requiring it, up from 35 percent in 2006. Tarceva had the next highest increase, with 62 percent of plans requiring prior authorization in 2009, up from 35 percent in 2006. Thalomid was next, with 68 percent of plans requiring prior authorization in 2009, up from 43 percent in 2006.

Geography and plan choice influence how much a person with cancer will spend out-of-pocket in Medicare Part D. Avalere and ACS CAN modeled hypothetical drug regimens for women with breast cancer and found that total out-of-pocket costs for a woman enrolled in AARP MedicareRx Saver in Florida will be about $1,985, while total out-of-pocket costs for beneficiaries enrolled in Humana PDP Standard in California will average about $2,551.

ACS CAN and the American Cancer Society are closely monitoring these issues as part of their nationwide efforts to ensure access to quality, affordable health care for all Americans. The organizations believe that the health care system needs to be retooled with an emphasis on prevention and early detection; meaningful health insurance that is adequate, affordable, available and administratively simple; and reducing pain and suffering with an emphasis on quality of life.

Avalere continues to analyze Medicare drug benefit data. Since the inception of the Medicare drug program, Avalere has used its proprietary DataFrame(R) database to track trends in drug pricing, plan strategy and structure, and the beneficiary experience.

-----
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page